DK1263504T3 - Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina - Google Patents

Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina

Info

Publication number
DK1263504T3
DK1263504T3 DK01918208T DK01918208T DK1263504T3 DK 1263504 T3 DK1263504 T3 DK 1263504T3 DK 01918208 T DK01918208 T DK 01918208T DK 01918208 T DK01918208 T DK 01918208T DK 1263504 T3 DK1263504 T3 DK 1263504T3
Authority
DK
Denmark
Prior art keywords
compounds
treatment
retinal disorders
activity useful
external retinal
Prior art date
Application number
DK01918208T
Other languages
Danish (da)
English (en)
Inventor
Mark R Hellberg
Robert J Collier Jr
Michael A Kapin
Thomas R Dean
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DK1263504T3 publication Critical patent/DK1263504T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
DK01918208T 2000-03-17 2001-02-23 Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina DK1263504T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
PCT/US2001/005700 WO2001070222A2 (en) 2000-03-17 2001-02-23 Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Publications (1)

Publication Number Publication Date
DK1263504T3 true DK1263504T3 (da) 2003-12-08

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01918208T DK1263504T3 (da) 2000-03-17 2001-02-23 Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina

Country Status (18)

Country Link
EP (3) EP1263434A1 (enExample)
JP (5) JP2003527423A (enExample)
KR (3) KR20030016239A (enExample)
CN (2) CN1198605C (enExample)
AR (1) AR028258A1 (enExample)
AT (1) ATE247507T1 (enExample)
AU (5) AU2001238552A1 (enExample)
BR (3) BR0109193A (enExample)
CA (3) CA2400637A1 (enExample)
DE (1) DE60100625T2 (enExample)
DK (1) DK1263504T3 (enExample)
ES (1) ES2204848T3 (enExample)
MX (3) MXPA02009071A (enExample)
PL (1) PL203709B1 (enExample)
PT (1) PT1263504E (enExample)
TW (1) TWI268777B (enExample)
WO (3) WO2001070223A1 (enExample)
ZA (1) ZA200206350B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の5−ht2および5−ht1aアゴニスト活性を有する化合物
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CN113840600B (zh) 2019-02-27 2026-02-13 加利福尼亚大学董事会 用于治疗脑疾病的n-取代吲哚和其他杂环化合物
KR20240150417A (ko) 2021-12-15 2024-10-15 델릭스 테라퓨틱스, 인크. 페녹시 및 벤질옥시로 치환된 사이코플라스토겐 및 그의 용도
WO2023118544A1 (en) * 2021-12-23 2023-06-29 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下1▼―ブロッカー点眼剤
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の5−ht2および5−ht1aアゴニスト活性を有する化合物

Also Published As

Publication number Publication date
JP2003527423A (ja) 2003-09-16
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
ATE247507T1 (de) 2003-09-15
TWI268777B (en) 2006-12-21
PT1263504E (pt) 2003-12-31
WO2001070223A1 (en) 2001-09-27
WO2001070222A2 (en) 2001-09-27
KR20030009390A (ko) 2003-01-29
JP2011037901A (ja) 2011-02-24
BR0109230A (pt) 2003-06-03
EP1263434A1 (en) 2002-12-11
DE60100625T2 (de) 2004-02-26
MXPA02009071A (es) 2003-05-23
CA2400637A1 (en) 2001-09-27
MXPA02009073A (es) 2003-03-12
HK1051504A1 (en) 2003-08-08
JP2003527427A (ja) 2003-09-16
AU4531001A (en) 2001-10-03
WO2001070222A3 (en) 2002-07-25
ES2204848T3 (es) 2004-05-01
AU2005202600B2 (en) 2008-07-31
MXPA02009072A (es) 2003-03-12
CA2400639A1 (en) 2001-09-27
AR028258A1 (es) 2003-04-30
WO2001070230A3 (en) 2002-04-25
WO2001070230A2 (en) 2001-09-27
KR100749191B1 (ko) 2007-08-13
CN1418100A (zh) 2003-05-14
KR20030016239A (ko) 2003-02-26
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
AU2001239836A1 (en) 2001-10-03
EP1263504B1 (en) 2003-08-20
JP2003527422A (ja) 2003-09-16
BR0109193A (pt) 2003-05-27
JP4789231B2 (ja) 2011-10-12
EP1267878A2 (en) 2003-01-02
CA2400639C (en) 2011-08-16
ZA200206350B (en) 2003-08-08
JP2011153158A (ja) 2011-08-11
CN1418121A (zh) 2003-05-14
CA2399985A1 (en) 2001-09-27
PL203709B1 (pl) 2009-11-30
EP1263504A2 (en) 2002-12-11
DE60100625D1 (de) 2003-09-25
CN1198605C (zh) 2005-04-27
PL358306A1 (en) 2004-08-09
KR20020082885A (ko) 2002-10-31

Similar Documents

Publication Publication Date Title
DK1263504T3 (da) Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina
IL176393A0 (en) Patterned laser treatment of the retina
PT1202722E (pt) Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
DK1228032T3 (da) Præparater, som indeholder hydroxyicosatetraensyrederivater, og fremgangsmåder til anvendelse ved behandling af öjentörhedslidelser
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DE602005021501D1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DE60307632D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
DE60008935D1 (de) Pyridinsulfonylharnstoffderivate mit herbizider wirkung
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
EE200300540A (et) 4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse või seedetrakti häirete ravis
DE60228764D1 (de) R-bambuterol, seine herstellung und therapeutische verwendungen
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
NO20031414D0 (no) Ny oksabispidinforbindelse som er nyttig i behandlingen av hjertearrytmier
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
DK1463563T3 (da) Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
EE200300542A (et) 4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse või seedetrakti häirete ravis
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde